<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An update from Genor Biopharma Holdings Limited ( (HK:6998) ) is now available. Edding Genor has been advancing GB261 through a global licensing strategy, having granted Candid Therapeutics exclusive rights outside Greater China to develop and commercialize the bispecific antibody. The deal structure combines equity participation with a double‑digit million‑dollar upfront payment, up to US$443 million in milestones, and tiered royalties, aligning the company’s interests with GB261’s long‑term commercial success. The strategic outlook for GB261 has further improved after Belgium’s UCB agreed to acquire Candid Therapeutics for up to US$2.2 billion, subject to regulatory approvals, potentially bringing a larger, well‑capitalized partner behind the asset. GB261 has demonstrated an encouraging safety and efficacy balance in Phase I/II lymphoma studies, and multiple trials in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are underway, broadening its therapeutic and commercial potential. More about Genor Biopharma Holdings Limited Edding Genor Group Holdings Limited, formerly Genor Biopharma, is a Cayman-incorporated biopharmaceutical group focused on developing innovative antibody-based therapies. Its pipeline includes GB261, a differentiated bispecific antibody targeting CD3 and CD20 for treating B‑cell lymphoma and autoimmune diseases, with an emphasis on both oncology and immunology indications. YTD Price Performance: 1.67% Average Trading Volume: 2,069,136 Technical Sentiment Signal: Buy Current Market Cap: HK$6.12B For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.</div>

IBBQ

LABU

ARKG

Edding Genor's GB261 is gaining traction as UCB plans to acquire Candid Therapeutics for up to $2.2 billion, enhancing the asset's commercial prospects. Genor Biopharma has licensed GB261, a bispecific antibody, to Candid for development outside Greater China, with a deal involving upfront payments and milestone incentives. GB261 shows promise in Phase I/II lymphoma studies and is being tested for autoimmune diseases. The company, focused on innovative antibody therapies, has a market cap of HK$6.12 billion and a year-to-date price performance of 1.67%.

Tip Ranks

United Community Banks

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

EDDING GENOR

UCB S.A.

Edding Genor’s GB261 Gains Momentum as UCB Moves to Acquire Licensee Candid Therapeutics